Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma

A small molecule inhibitor of NF-κB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells

(2009) Jason Ho Ting Wong et al.   CANCER LETTERS

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

(2008) Albana Cumashi et al.   CANCER LETTERS

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

(2008) Brigette B. Y. Ma et al.   CANCER SCIENCE

Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy

(2008) Marcus Czabanka et al.   INTERNATIONAL JOURNAL OF CANCER

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

(2008) John M. Maris et al.   PEDIATRIC BLOOD & CANCER

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

(2008) Guru Sonpavde et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS